What's Happening?
Nexalin Technology, Inc. has published a peer-reviewed study in BMC Psychiatry highlighting the effects of its Deep Intracranial Frequency Stimulation (DIFS) technology on adolescents with non-suicidal self-injury (NSSI). The study involved six female
adolescent patients who underwent 21 days of 77.5 Hz, 15 mA stimulation using Nexalin's device. Results indicated statistically significant reductions in self-injury behaviors and depressive symptoms, along with changes in brain-network activity and connectivity. The study also reported improvements in anxiety and sleep quality measures, with no significant adverse effects observed. Nexalin's CEO, Mark White, emphasized the potential of the technology to offer drug-free alternatives in mental health treatment, supporting higher efficacy and enhanced outcomes in treatment-resistant populations.
Why It's Important?
The findings from Nexalin's study are significant as they offer preliminary evidence for a non-invasive treatment option for adolescents struggling with self-injury and depression. This could potentially transform mental health treatment by providing safer alternatives to medication, which often come with side effects. The study supports the broader relevance of Nexalin's technology across multiple indications, potentially expanding its market reach. As mental health issues continue to rise, especially among adolescents, innovative treatments like DIFS could play a crucial role in addressing these challenges, offering hope for improved mental health outcomes and quality of life.
What's Next?
Nexalin plans to further investigate its DIFS technology through larger randomized controlled trials to validate the preliminary findings. The company is also expanding its digital health ecosystem with the launch of NeuroCare, an AI-designed virtual clinic platform, in collaboration with the University of California, San Diego. This initiative aims to increase patient access, reduce costs, and provide long-term care and monitoring for brain-health indications. As Nexalin continues to publish peer-reviewed studies, it seeks to broaden the relevance of its technology and establish a stronger foothold in the mental health treatment market.
